Being diagnosed with medullary thyroid cancer (MTC)—a rare and sometimes aggressive type of thyroid cancer—can feel overwhelming. But a new targeted therapy, LuciVande, developed by Lucius Pharmaceuticals, offers a fresh option for patients, especially when the cancer has spread or become difficult to treat.
LuciVande is available in 100 mg and 300 mg tablets. Its active ingredient, Vandetanib, is a targeted therapy that helps slow cancer growth and ease symptoms—providing a better quality of life for people living with advanced MTC.
How LuciVande Works in the Body
Unlike traditional cancer treatments that attack all fast-growing cells, LuciVande zeroes in on specific cancer-driving signals, helping to reduce side effects and focus on stopping cancer at its source.
1. Blocks Tumor Blood Supply (VEGFR)
Cancer needs a steady supply of blood to grow. LuciVande blocks angiogenesis—the process tumors use to build new blood vessels—cutting off the nutrients they rely on.
2. Slows Down Cell Growth (EGFR)
Cancer cells divide uncontrollably. LuciVande stops one of the key growth signals—EGFR—slowing the cancer’s spread.
3. Targets Genetic Mutations (RET)
Many MTC cases are driven by changes in the RET gene. LuciVande blocks this mutation at the source, helping prevent cancer growth from the ground up.
Why LuciVande Stands Out
- Precision: It targets only the cancer-related pathways—not all dividing cells.
- Tolerability: While side effects may occur, patients often find it easier to manage than chemotherapy.
- Personalization: It’s especially effective in patients with RET or other specific gene mutations.
For Patients and Caregivers
LuciVande isn’t just another pill—it represents years of progress in cancer care. While it’s not a cure, it may:
- Extend the time you have with loved ones
- Improve your ability to manage symptoms
- Fit into your overall care plan with greater ease
📌 If you have questions or want to know if LuciVande is right for you, talk to your doctor. You don’t have to face cancer alone.
